622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma

• Sunil Reddy,
• Susan Swetter,
• Emanual Maverakis,
• Mohammad Usman Ahmad,
• Michael C Lowe,
• Saurabh Sharma,
• Mamatha Serasanambati,
• Chris Applebee,
• Elena Safrygina,
• Banafshe Larijani,
• Amanda Kirane,
• Allison B Warner

Affiliations

Sunil Reddy

6Stanford Cancer Institute, Redwood City, CA, USA

Susan Swetter

Aff3 grid.168010.e0000000419368956Stanford University Dermatology Stanford CA USA

Emanual Maverakis

4University of California, Davis, Sacramento, CA, USA

Mohammad Usman Ahmad

1Stanford University, Palo Alto, CA, USA

Michael C Lowe

3Emory University School of Medicine, Atlanta, GA, USA

Saurabh Sharma

2School of Medicine, Stanford University, Palo Alto, CA, USA

Mamatha Serasanambati

1Stanford University, Palo Alto, CA, USA

Chris Applebee

3University of Bath, Bath, UK, UK

Elena Safrygina

3University of Bath, Bath, UK, UK

Banafshe Larijani

3University of Bath, Bath, UK, UK

Amanda Kirane

1Stanford University, Palo Alto, CA, USA

Allison B Warner

4Memorial Sloan Kettering Cancer Center, New York, NY, USA